Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

PaperCitations, authors & open-access status

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 391 citations, 2015 year and bronze oa status.

391
Citations
2015
Year
bronze
OA Status

Related on ScholarIQ

Baohui Han
Author
You Lü
Author
Yi‐Long Wu
Author
Journal of Clinical Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
470M+ articles · free account